Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Type 2 Diabetes Mellitus Medication: Antidiabetics, Biguanides, Antidiabetics, Glucagon-like Peptide-1 Agonists, Antidiabetics, SGLT2 Inhibitors, Antidiabetics, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors, Antidiabetics, Sulfonylureas, Antidiabetics, Meglitinide Derivatives, Antidiabetics, Alpha-Glucosidase Inhibitors, Antidiabetics, Thiazolidinediones, Aldosterone Antagonists, Selective, Antidiabetics, Amylinomimetics, Bile Acid Sequestrants, Antiparkinson Agents, Dopamine Agonists, Antidiabetics, Rapid-Acting Insulins, Antidiabetics, Short-Acting Insulins, Antidiabetics, Intermediate-Acting Insulins, Antidiabetics, Long-Acting Insulins

Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care . 2003 Jan. 26 Suppl 1:S5-20. [QxMD MEDLINE Link] . Parker ED, Lin J, Mahoney T, et al. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care . 2024

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

  • Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care . 2003 Jan. 26 Suppl 1:S5-20. [QxMD MEDLINE Link] .
  • Parker ED, Lin J, Mahoney T, et al. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care . 2024 Jan 1. 47 (1):26-43. [QxMD MEDLINE Link] . [Full Text] .
  • Pauza AG, Thakkar P, Tasic T, et al. GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition. Circ Res . 2022 Feb 1. CIRCRESAHA121319874. [QxMD MEDLINE Link] . [Full Text] .
  • Sweet pressure – scientists discover link between high blood pressure and diabetes. University of Bristol. Available at https://www.bristol.ac.uk/news/2022/february/blood-pressure-diabetes.html . February 1, 2022; Accessed: February 2, 2022.
  • Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet . 2004 Jan 10. 363(9403):157-63. [QxMD MEDLINE Link] .
  • Wei GS, Coady SA, Goff DC Jr, et al. Blood pressure and the risk of developing diabetes in African Americans and Whites: ARIC, CARDIA, and the framingham heart study. Diabetes Care . 2011 Apr. 34(4):873-9. [QxMD MEDLINE Link] . [Full Text] .
  • Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diabetes Care . 1999 Jun. 22(6):944-50. [QxMD MEDLINE Link] .
  • Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D, Wingard DL. Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. Diabetes Care . 1998 Oct. 21(10):1652-8. [QxMD MEDLINE Link] .
  • Li Y, Qi Q, Workalemahu T, Hu FB, Qi L. Birth Weight, Genetic Susceptibility, and Adulthood Risk of Type 2 Diabetes. Diabetes Care . 2012 Aug 24. [QxMD MEDLINE Link] .
  • Slining MM, Kuzawa CW, Mayer-Davis EJ, Adair LS. Evaluating the indirect effect of infant weight velocity on insulin resistance in young adulthood: a birth cohort study from the Philippines. Am J Epidemiol . 2011 Mar 15. 173(6):640-8. [QxMD MEDLINE Link] . [Full Text] .
  • Fang M, Jeon Y, Echouffo-Tcheugui JB, Selvin E. Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes. Ann Intern Med . 2023 Mar. 176 (3):427-9. [QxMD MEDLINE Link] . [Full Text] .
  • Wang J, Luben R, Khaw KT, Bingham S, Wareham NJ, Forouhi NG. Dietary energy density predicts the risk of incident type 2 diabetes: the European Prospective Investigation of Cancer (EPIC)-Norfolk Study. Diabetes Care . 2008 Nov. 31(11):2120-5. [QxMD MEDLINE Link] . [Full Text] .
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S27-S49. [QxMD MEDLINE Link] . [Full Text] .
  • Grant SFA. The TCF7L2 Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes. Diabetes Care . 2019 Sep. 42 (9):1624-9. [QxMD MEDLINE Link] .
  • Cauchi S, Meyre D, Dina C, et al. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes . 2006 Oct. 55 (10):2903-8. [QxMD MEDLINE Link] .
  • Sale MM, Smith SG, Mychaleckyj JC, et al. Variants of the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes . 2007 Oct. 56 (10):2638-42. [QxMD MEDLINE Link] .
  • Scott LJ, Bonnycastle LL, Willer CJ, et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes . 2006 Sep. 55 (9):2649-53. [QxMD MEDLINE Link] .
  • Groves CJ, Zeggini E, Minton J, et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes . 2006 Sep. 55 (9):2640-4. [QxMD MEDLINE Link] .
  • Miyake K, Horikawa Y, Hara K, et al. Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. J Hum Genet . 2008. 53 (2):174-80. [QxMD MEDLINE Link] .
  • Chandak GR, Janipalli CS, Bhaskar S, et al. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia . 2007 Jan. 50 (1):63-7. [QxMD MEDLINE Link] .
  • Chang YC, Chang TJ, Jiang YD, et al. Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes . 2007 Oct. 56 (10):2631-7. [QxMD MEDLINE Link] .
  • Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet . 2006 Mar. 38 (3):320-3. [QxMD MEDLINE Link] .
  • Ding W, Xu L, Zhang L, et al. Meta-analysis of association between TCF7L2 polymorphism rs7903146 and type 2 diabetes mellitus. BMC Med Genet . 2018 Mar 7. 19 (1):38. [QxMD MEDLINE Link] .
  • Zhu L, Xie Z, Lu J, et al. TCF7L2 rs290481 T>C polymorphism is associated with an increased risk of type 2 diabetes mellitus and fasting plasma glucose level. Oncotarget . 2017 Sep 29. 8 (44):77000-8. [QxMD MEDLINE Link] . [Full Text] .
  • Delvecchio M, Pastore C, Giordano P. Treatment Options for MODY Patients: A Systematic Review of Literature. Diabetes Ther . 2020 Aug. 11 (8):1667-85. [QxMD MEDLINE Link] . [Full Text] .
  • Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet . 2006 Jan. 43(1):84-90. [QxMD MEDLINE Link] . [Full Text] .
  • Raeder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet . 2006 Jan. 38(1):54-62. [QxMD MEDLINE Link] .
  • van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet . 1992 Aug. 1(5):368-71. [QxMD MEDLINE Link] .
  • Castellino AM. Genetically Lowered Birth Weight May Cause Type 2 Diabetes. Medscape Medical News . July 4, 2016. [Full Text] .
  • Wang T, Huang T, Li Y, Zheng Y, Manson JE, Hu FB, et al. Low birthweight and risk of type 2 diabetes: a Mendelian randomisation study. Diabetologia . 2016 Jun 23. [QxMD MEDLINE Link] .
  • Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med . 2010 Nov 22. 170(21):1884-91. [QxMD MEDLINE Link] . [Full Text] .
  • Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia . 2010 Dec. 53(12):2480-6. [QxMD MEDLINE Link] . [Full Text] .
  • Mizuki Y, Sakamoto S, Okahisa Y, et al. Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus. Int J Neuropsychopharmacol . 2021 May 18. 24 (5):367-82. [QxMD MEDLINE Link] . [Full Text] .
  • Miedlich SU, Lamberti JS. Connecting the dots: Understanding and addressing the metabolic impact of antipsychotic and antidepressant medications. Ann N Y Acad Sci . 2025 Apr. 1546 (1):35-57. [QxMD MEDLINE Link] .
  • Holt RIG. Association Between Antipsychotic Medication Use and Diabetes. Curr Diab Rep . 2019 Sep 2. 19 (10):96. [QxMD MEDLINE Link] . [Full Text] .
  • Feig DS, Shah BR, Lipscombe LL, Wu CF, Ray JG, Lowe J, et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med . 2013 Apr. 10(4):e1001425. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. New Global Registry Investigates COVID-19 and New-Onset Diabetes. Medscape Medical News . 2020 Jun 13. [Full Text] .
  • Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol . 2022 May. 10 (5):311-21. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. 'Profound Implications': COVID Ups Diabetes Risk 40% a Year Later. Medscape Medical News . 2022 Mar 23. [Full Text] .
  • Tang X, Uhl S, Zhang T, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab . 2021 May 19. [QxMD MEDLINE Link] . [Full Text] .
  • Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab . 2021 May 18. [QxMD MEDLINE Link] . [Full Text] .
  • Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep . 2022 Jan 14. 71 (2):59-65. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. COVID-19 Associated With Increased Diabetes Risk in Youth. Medscape Medical News . 2022 Jan 10. [Full Text] .
  • Cromer SJ, Colling C, Schatoff D, et al. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complications . 2022 Feb 4. 108145. [QxMD MEDLINE Link] . [Full Text] .
  • Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A . 2010 Sep 14. 107(37):16009-12. [QxMD MEDLINE Link] . [Full Text] .
  • Philippe MF, Benabadji S, Barbot-Trystram L, Vadrot D, Boitard C, Larger E. Pancreatic volume and endocrine and exocrine functions in patients with diabetes. Pancreas . 2011 Apr. 40(3):359-63. [QxMD MEDLINE Link] .
  • Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care . 2010 Oct. 33(10):2225-31. [QxMD MEDLINE Link] . [Full Text] .
  • Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. J Clin Endocrinol Metab . 2011 Feb. 96(2):447-53. [QxMD MEDLINE Link] .
  • Lawrence JM, Casagrande SS, Herman WH, et al. Genetics of Type 2 Diabetes. Diabetes in America . 2023 Dec 20. [QxMD MEDLINE Link] . [Full Text] .
  • Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet . 2010 Feb. 42(2):142-8. [QxMD MEDLINE Link] . [Full Text] .
  • Chiefari E, Tanyolac S, Paonessa F, Pullinger CR, Capula C, Iiritano S, et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA . 2011 Mar 2. 305(9):903-12. [QxMD MEDLINE Link] .
  • Testa R, Olivieri F, Sirolla C, Spazzafumo L, Rippo MR, Marra M, et al. Leukocyte telomere length is associated with complications of type 2 diabetes mellitus. Diabet Med . 2011 Nov. 28(11):1388-94. [QxMD MEDLINE Link] .
  • Krssak M, Winhofer Y, Gobl C, Bischof M, Reiter G, Kautzky-Willer A, et al. Insulin resistance is not associated with myocardial steatosis in women. Diabetologia . 2011 Jul. 54(7):1871-8. [QxMD MEDLINE Link] .
  • Cao X, Wang N, Yang M, Zhang C. Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease. Int J Mol Sci . 2025 Jul 20. 26 (14): [QxMD MEDLINE Link] . [Full Text] .
  • Feingold KR, Ahmed SF, Anawalt B, et al. Triglyceride Lowering Drugs. Endotext . 2025 Jun 22. [QxMD MEDLINE Link] . [Full Text] .
  • Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents?. Ann Intern Med . 1996 Jan 1. 124(1 Pt 2):110-6. [QxMD MEDLINE Link] .
  • Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care . 1999 Apr. 22(4):562-8. [QxMD MEDLINE Link] .
  • Sjöholm Å, Bennet L, Nilsson PM. Cognitive dysfunction in diabetes - the 'forgotten' diabetes complication: a narrative review. Scand J Prim Health Care . 2025 Jun. 43 (2):448-54. [QxMD MEDLINE Link] . [Full Text] .
  • Zheng F, Yan L, Yang Z, Zhong B, Xie W. HbA 1c , diabetes and cognitive decline: the English Longitudinal Study of Ageing. Diabetologia . 2018 Jan 25. [QxMD MEDLINE Link] . [Full Text] .
  • Melville NA. HbA1c Levels in Diabetes Linked to Cognitive Decline. Medscape Medical News . 2018 Jan 30. [Full Text] .
  • McCall B. Causal Link Found for Type 2 Diabetes and Lung Complications. Medscape News UK . 2023 Apr 28. [Full Text] .
  • Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol . 2018 Mar 1. [QxMD MEDLINE Link] .
  • Davenport L. Diabetes Consists of Five Types, Not Two, Say Researchers. Medscape Medical News . 2018 Mar 1. [Full Text] .
  • Centers for Disease Control and Prevention. National Diabetes Statistics Report. CDC. Reviewed January 18, 2022; Accessed: January 28, 2022.
  • Tucker ME. More Than 1 in 10 People in US Have Diabetes, CDC Says. Medscape Medical News . 2022 Jan 26. [Full Text] .
  • US Centers for Disease Control and Prevention. Spotlight on Diabetes Data: Prediabetes in US Adolescents. CDC. Available at https://gis.cdc.gov/grasp/diabetes/diabetesatlas-spotlight.html . Accessed: August 15, 2025.
  • Koyama AK, Cheng YJ, Brinks R, et al. Trends in lifetime risk and years of potential life lost from diabetes in the United States, 1997-2018. PLoS One . 2022. 17 (5):e0268805. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. IDF Atlas: 1 in 10 Adults Worldwide Now Has Diabetes. Medscape Medical News . 2021 Dec 7. [Full Text] .
  • US Centers for Disease Control and Prevention. National Diabetes Statistics Report. CDC. Available at https://gis.cdc.gov/grasp/diabetes/diabetesatlas-statsreport.html . March 11, 2026; Accessed: April 21, 2026.
  • Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care . 2010 May. 33(5):1090-6. [QxMD MEDLINE Link] . [Full Text] .
  • White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes . 2010 May. 59(5):1244-53. [QxMD MEDLINE Link] . [Full Text] .
  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet . 1998 Sep 12. 352(9131):837-53. [QxMD MEDLINE Link] .
  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med . 2008 Oct 9. 359(15):1577-89. [QxMD MEDLINE Link] .
  • Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med . 2008 Jun 12. 358(24):2630-3. [QxMD MEDLINE Link] .
  • Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol . 2009 Jan 20. 53(3):298-304. [QxMD MEDLINE Link] .
  • Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med . 2009 Jan 8. 360(2):129-39. [QxMD MEDLINE Link] .
  • Tian J, Ohkuma T, Cooper M, et al. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A(1c) in the ADVANCE Trial. Diabetes Care . 2020 Jun. 43 (6):1293-9. [QxMD MEDLINE Link] . [Full Text] .
  • Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet . 2011 Jul 9. 378(9786):156-67. [QxMD MEDLINE Link] . [Full Text] .
  • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med . 2008 Feb 7. 358(6):580-91. [QxMD MEDLINE Link] .
  • National Center for Health Statistics. Mortality in the United States, 2023. CDC. Available at https://www.cdc.gov/nchs/products/databriefs/db521.htm . December 2024; Accessed: August 29, 2025.
  • Vision Loss Expert Group of the Global Burden of Disease Study, GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 2000 to 2020. Eye (Lond) . 2024 Aug. 38 (11):2047-57. [QxMD MEDLINE Link] . [Full Text] .
  • Burrows NR, Koyama A, Pavkov ME. Reported Cases of End-Stage Kidney Disease - United States, 2000-2019. MMWR Morb Mortal Wkly Rep . 2022 Mar 18. 71 (11):412-5. [QxMD MEDLINE Link] . [Full Text] .
  • GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol . 2024 Apr. 23 (4):344-81. [QxMD MEDLINE Link] . [Full Text] .
  • Verma S, Leiter LA, Mangla KK, Nielsen NF, Hansen Y, Bonaca MP. Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review. Diabetes Ther . 2024 Sep. 15 (9):1893-961. [QxMD MEDLINE Link] . [Full Text] .
  • Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med . 2011 Mar 14. 171(5):404-10. [QxMD MEDLINE Link] .
  • Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med . 2011 Mar 3. 364(9):829-41. [QxMD MEDLINE Link] .
  • Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjornsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia . 2012 Aug 16. [QxMD MEDLINE Link] .
  • Centers for Disease Control and Prevention. Underlying Conditions and the Higher Risk for Severe COVID-19. CDC. Available at https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html . February 6, 2025; Accessed: September 12, 2025.
  • Chen Y, Yang D, Cheng B, et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care . 2020 May 14. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. 'The Story Unfolding Is Worrisome' for Diabetes and COVID-19. Medscape Medical News . 2020 May 26. [Full Text] .
  • Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol . 2020 Jul. 14 (4):813-21. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. Pay Attention to In-Hospital Glucose to Save Lives in COVID-19. Medscape Medical News . 2020 Apr 20. [Full Text] .
  • Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol . 2020 Aug 13. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. Newly Published Articles Inform on COVID-19 Risk by Diabetes Type. Medscape Medical News . 2020 Aug 17. [Full Text] .
  • Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab . 2020 May 1. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. Largest Study to Date Links Glucose Control to COVID-19 Outcomes. Medscape Medical News . 2020 May 14. [Full Text] .
  • Murphy HR, Steel SA, Roland JM, Morris D, Ball V, Campbell PJ, et al. Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med . 2011 Sep. 28(9):1060-7. [QxMD MEDLINE Link] . [Full Text] .
  • Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care . 1992 Jul. 15(7):815-9. [QxMD MEDLINE Link] .
  • Nainggolan L. Dawn Phenomenon Affects Half of Type 2 Diabetes Patients. Medscape Medical News . Nov 7 2013. [Full Text] .
  • Monnier L, Colette C, Dejager S, et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?. Diabetes Care . 2013 Oct 29. [QxMD MEDLINE Link] . [Full Text] .
  • Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA . 2007 Aug 22. 298(8):902-16. [QxMD MEDLINE Link] .
  • Frank RN. Diabetic retinopathy. N Engl J Med . 2004 Jan 1. 350(1):48-58. [QxMD MEDLINE Link] .
  • Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care . 2008 Aug. 31 (8):1679-85. [QxMD MEDLINE Link] . [Full Text] .
  • [Guideline] Diagnosis and classification of diabetes mellitus. Diabetes Care . 2010 Jan. 33 Suppl 1:S62-9. [QxMD MEDLINE Link] . [Full Text] .
  • Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care . 2011 Jun. 34(6):1306-11. [QxMD MEDLINE Link] . [Full Text] .
  • Vijayakumar P, Nelson RG, Hanson RL, Knowler WC, Sinha M. HbA1c and the Prediction of Type 2 Diabetes in Children and Adults. Diabetes Care . 2017 Jan. 40 (1):16-21. [QxMD MEDLINE Link] . [Full Text] .
  • Davenport L. HbA1c Predicts Diabetes Risk in Children and Adolescents. Medscape Medical News . 2017 Jan 4. [Full Text] .
  • Gerstein HC, Islam S, Anand S, Almahmeed W, Damasceno A, Dans A, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia . 2010 Dec. 53(12):2509-17. [QxMD MEDLINE Link] . [Full Text] .
  • Suzuki S, Koga M, Amamiya S, Nakao A, Wada K, Okuhara K, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia . 2011 Sep. 54(9):2247-53. [QxMD MEDLINE Link] .
  • Wilson DM, Xing D, Cheng J, Beck RW, Hirsch I, Kollman C, et al. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care . 2011 Jun. 34(6):1315-7. [QxMD MEDLINE Link] . [Full Text] .
  • US Preventive Services Task Force. Prediabetes and type 2 diabetes: screening. USPSTF. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes . August 24, 2021; Accessed: September 19, 2025.
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S13-S26. [QxMD MEDLINE Link] . [Full Text] .
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 13. Older Adults: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S277-S296. [QxMD MEDLINE Link] . [Full Text] .
  • Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med . 2011 Mar 3. 364(9):818-28. [QxMD MEDLINE Link] .
  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet . 1998 Sep 12. 352(9131):854-65. [QxMD MEDLINE Link] .
  • [Guideline] Busko M. HbA1c Below 8% in Diabetes for 'Most' Says ACP, But Others Disagree. Medscape Medical News . 2018 Mar 5. [Full Text] .
  • [Guideline] Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med . 2018 Mar 6. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. Type 2 Diabetes 'Remission' Is a Reality, Say Major Organizations. Medscape Medical News . 2021 Sep 1. [Full Text] .
  • Riddle MC, Cefalu WT, Evans PH, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. J Clin Endocrinol Metab . 2021 Aug 30. [QxMD MEDLINE Link] . [Full Text] .
  • Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. Endocr Pract . 2026 Apr. 32 (4):473-518. [QxMD MEDLINE Link] . [Full Text] .
  • Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care . 2008 Nov. 31(11):2086-91. [QxMD MEDLINE Link] . [Full Text] .
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S183-S215. [QxMD MEDLINE Link] . [Full Text] .
  • Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA . 1999 Jun 2. 281(21):2005-12. [QxMD MEDLINE Link] .
  • UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care . 1998 Jan. 21(1):87-92. [QxMD MEDLINE Link] .
  • Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med . 2009 Mar 23. 169(6):616-25. [QxMD MEDLINE Link] .
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S50-S60. [QxMD MEDLINE Link] . [Full Text] .
  • Ozempic (semaglutide SC) [package insert]. Plainsboro, NJ: Novo Nordisk. January 2020. Available at [Full Text] .
  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med . 2016 Nov 10. 375 (19):1834-44. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. FDA Approves CVD Benefit for Once-Weekly Semaglutide. Medscape Medical News . 2020 Jan 17. [Full Text] .
  • Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA . 2019 Apr 16. 321 (15):1466-80. [QxMD MEDLINE Link] . [Full Text] .
  • Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care . 2019 Sep 17. [QxMD MEDLINE Link] .
  • Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet . 2019 Jul 6. 394 (10192):39-50. [QxMD MEDLINE Link] .
  • RYBELSUS® (semaglutide) tablets [package insert]. Plainsboro, NJ: Novo Nordisk Inc. October 2025. Available at [Full Text] .
  • Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care . 2009 May. 32(5):762-8. [QxMD MEDLINE Link] . [Full Text] .
  • Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med . 2011 Jan 18. 154(2):103-12. [QxMD MEDLINE Link] .
  • Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet . 2008 Oct 4. 372(9645):1240-50. [QxMD MEDLINE Link] .
  • Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract . 2012 Aug 24. [QxMD MEDLINE Link] .
  • Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab . 2011 May. 96(5):1301-10. [QxMD MEDLINE Link] .
  • Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, et al. Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care . 2012 Dec 28. [QxMD MEDLINE Link] .
  • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med . 2016 Jul 28. 375 (4):311-22. [QxMD MEDLINE Link] . [Full Text] .
  • Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med . 2019 Apr 28. [QxMD MEDLINE Link] .
  • Tucker M. FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes. Medscape Medical News. Available at https://www.medscape.com/viewarticle/831969 . Accessed: September 26, 2014.
  • Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care . 2014 Aug. 37(8):2159-67. [QxMD MEDLINE Link] .
  • Frias JP, Bonora E, Nevarez Ruiz LA, et al. Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11 (Abst 357-OR). Presented at the 80th Scientific sessions American of the Diabetes Association. 2020 Jun 12-16. Chicago, IL. Available at https://diabetes.diabetesjournals.org/content/69/Supplement_1/357-OR .
  • Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet . 2019 Jul 13. 394 (10193):121-30. [QxMD MEDLINE Link] .
  • Busko M. FDA approves weekly injectable diabetes drug: albiglutide. Medscape Medical News . April 15, 2014. [Full Text] .
  • Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol . 2014 Apr. 2 (4):289-97. [QxMD MEDLINE Link] .
  • Frías JP, Davies MJ, Rosenstock J, and the, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med . 2021 Aug 5. 385 (6):503-515. [QxMD MEDLINE Link] . [Full Text] .
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S61-S88. [QxMD MEDLINE Link] . [Full Text] .
  • Nainggolan L. FDA approves canagliflozin, a first-in-class diabetes drug. March 29, 2013. Medscape Medical News. Available at https://www.medscape.com/viewarticle/781709 . Accessed: April 2, 2013.
  • Tucker M. FDA Approves Dapagliflozin (Farxiga) for Type 2 Diabetes Treatment. Medscape Medical News. Available at https://www.medscape.com/viewarticle/818858 . Accessed: January 13, 2014.
  • Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol . 2013 Nov. 1(3):208-19. [QxMD MEDLINE Link] .
  • Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol . 2014 Jun 16. [QxMD MEDLINE Link] .
  • INVOKANA® (canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc. Revised December 2024. Available at [Full Text] .
  • FARXIGA® (dapagliflozin) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. Revised Jun 2024. Available at [Full Text] .
  • JARDIANCE® (empagliflozin tablets) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. Revised October 2025. Available at [Full Text] .
  • STEGLATRO® (ertugliflozin) [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC. Revised December 2024. Available at [Full Text] .
  • BRENZAVVY (bexagliflozin) [package insert]. Marlborough, MA: TheracosBio, LLC. Revised January 2023. Available at [Full Text] .
  • Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med . 2011 Nov. 28(11):1352-61. [QxMD MEDLINE Link] .
  • Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care . 2011 Feb. 34(2):369-74. [QxMD MEDLINE Link] . [Full Text] .
  • Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care . 2011 Nov. 34(11):2474-6. [QxMD MEDLINE Link] . [Full Text] .
  • Solerte SB, D'Addio F, Trevisan R, et al. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care . 2020 Sep 29. [QxMD MEDLINE Link] . [Full Text] .
  • Zoler ML. Fewer Deaths in Hospitalized COVID Diabetes Patients on Sitagliptin. Medscape Medical News . 2020 Oct 1. [Full Text] .
  • Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab . 2010 Nov. 95(11):4993-5002. [QxMD MEDLINE Link] .
  • Bellomo Damato A, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. Diabet Med . 2011 May. 28(5):560-6. [QxMD MEDLINE Link] .
  • Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care . 2011 Jul. 34(7):1601-4. [QxMD MEDLINE Link] . [Full Text] .
  • DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med . 2011 Mar 24. 364(12):1104-15. [QxMD MEDLINE Link] .
  • Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet . 2006 Sep 23. 368(9541):1096-105. [QxMD MEDLINE Link] .
  • Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabet Med . 2011 Aug. 28(8):948-64. [QxMD MEDLINE Link] .
  • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet . 2005 Oct 8. 366(9493):1279-89. [QxMD MEDLINE Link] .
  • Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care . 2011 Apr. 34(4):916-22. [QxMD MEDLINE Link] . [Full Text] .
  • Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care . 2011 Apr. 34(4):923-9. [QxMD MEDLINE Link] . [Full Text] .
  • Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care . 2011 Jun. 34(6):1369-71. [QxMD MEDLINE Link] . [Full Text] .
  • Hickson RP, Cole AL, Dusetzina SB. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. J Manag Care Spec Pharm . 2019 Jan. 25 (1):72-9. [QxMD MEDLINE Link] . [Full Text] .
  • Zoler ML. FDA Approves Finerenone (Kerendia) for Slowing CKD in Type 2 Diabetes. Medscape Medical News . 2021 Jul 12. [Full Text] .
  • Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med . 2020 Dec 3. 383 (23):2219-29. [QxMD MEDLINE Link] . [Full Text] .
  • US Food and Drug Administration. FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complications in Adults with Chronic Kidney Disease Associated with Type 2 Diabetes. FDA. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease . July 9, 2021; Accessed: July 15, 2021.
  • Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev . 2011 Oct 5. CD006423. [QxMD MEDLINE Link] .
  • Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract . 2010 Jul-Aug. 16(4):617-28. [QxMD MEDLINE Link] .
  • Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract . 2010 Jul-Aug. 16(4):629-40. [QxMD MEDLINE Link] .
  • Sando KR, Taylor J. Bromocriptine: its place in type 2 diabetes Tx. J Fam Pract . 2011 Nov. 60(11):E1-5. [QxMD MEDLINE Link] .
  • Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care . 2010 Jul. 33(7):1503-8. [QxMD MEDLINE Link] . [Full Text] .
  • Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet . 2011 Mar 12. 377(9769):924-31. [QxMD MEDLINE Link] .
  • Awiqli (insulin icodec-abae) [package insert]. Plainsboro, NJ: Novo Nordisk Inc. March 2026. Available at [Full Text] .
  • Tucker ME. FDA Approves First Once-Weekly Insulin for Type 2 Diabetes. Medscape Medical News . 2026 Mar 30. [Full Text] .
  • Afrezza (insulin inhaled) prescribing information [package insert]. Valencia CA, United States: MannKind Corporation. June 2014. Available at [Full Text] .
  • Boule NG, Robert C, Bell GJ, Johnson ST, Bell RC, Lewanczuk RZ, et al. Metformin and exercise in type 2 diabetes: examining treatment modality interactions. Diabetes Care . 2011 Jul. 34(7):1469-74. [QxMD MEDLINE Link] . [Full Text] .
  • Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care . 2011 Apr. 34(4):855-7. [QxMD MEDLINE Link] . [Full Text] .
  • Chen MJ, Jovanovic A, Taylor R. Utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care . 2010 Dec. 33(12):2552-4. [QxMD MEDLINE Link] . [Full Text] .
  • Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med . 2008 Oct 21. 149(8):549-59. [QxMD MEDLINE Link] .
  • Porcellati F, Lucidi P, Rossetti P, Candeloro P, Andreoli AM, Marzotti S, et al. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Diabetes Care . 2011 Dec. 34(12):2521-3. [QxMD MEDLINE Link] . [Full Text] .
  • Baldwin D, Zander J, Munoz C, Raghu P, Delange-Hudec S, Lee H, et al. A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency. Diabetes Care . 2012 Jun 14. [QxMD MEDLINE Link] .
  • [Guideline] Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R. Consensus statement by the american association of clinical endocrinologists/american college of endocrinology insulin pump management task force. Endocr Pract . 2014 May 1. 20(5):463-89. [QxMD MEDLINE Link] .
  • [Guideline] Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract . 2021 Jun. 27 (6):505-37. [QxMD MEDLINE Link] . [Full Text] .
  • Tucker ME. 'A Better Picture': First AACE Guidelines on Diabetes Technology. Medscape Medical News . 2021 May 31. [Full Text] .
  • Fritsche A, Larbig M, Owens D, Haring HU. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab . 2010 Feb. 12(2):115-23. [QxMD MEDLINE Link] .
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S132-49. [QxMD MEDLINE Link] . [Full Text] .
  • Lu ZX, Walker KZ, O'Dea K, Sikaris KA, Shaw JE. A1C for screening and diagnosis of type 2 diabetes in routine clinical practice. Diabetes Care . 2010 Apr. 33(4):817-9. [QxMD MEDLINE Link] . [Full Text] .
  • [Guideline] American Diabetes Association Professional Practice Committee for Diabetes*. 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care . 2026 Jan 1. 49 (Supplement_1):S150-65. [QxMD MEDLINE Link] . [Full Text] .
  • Kompala T, Neinstein A. A new era: increasing continuous glucose monitoring use in type 2 diabetes. Am J Manag Care . 2019 Mar. 25 (4 Spec No.):SP123-6. [QxMD MEDLINE Link] . [Full Text] .
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

Ketosis-Prone Type 2 Diabetes Medication: Antidiabetics, Alpha-Glucosidase Inhibitors, Antidiabetics, Amylinomimetics, Antidiabetics, Biguanides, Antidiabetics, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors, Antidiabetics, Glucagon-like Peptide-1 Agonists, Antidiabetics, Glucose-dependent Insulinotropic Polypeptides, Antidiabetics, Insulins, Antidiabetics, Meglitinide Derivatives, Antidiabetics, SGLT2 Inhibitors, Antidiabetics, Sulfonylureas, Antidiabetics, Thiazolidinediones, Antiparkinson Agents, Dopamine Agonists, Bile Acid Sequestrants, Hypoglycemia Antidotes

Gaba R, Mehta P, Balasubramanyam A. Evaluation and management of ketosis-prone diabetes. Expert Rev Endocrinol Metab . 2019 Jan. 14 (1):43-8. [QxMD MEDLINE Link] . Boike S, Mir M, Rauf I, et al. Ketosis-prone …

Read guide →